Advances in gene therapy for hemophilia.

Advances in gene therapy for hemophilia. J Biosci. 2020;45: Authors: Robles-Rodriguez OA, Pe Rez-Trujillo JJ, Villanueva-Olivo A, Villarreal-Martinez L, Marfil-Rivera LJ, Rodriguez-Rocha H, Garcia-Garcia A, Saucedo-Cardenas O, Loera-Arias MJ, Oca-Luna RM Abstract Hemophilia is a hereditary disorder that can be life-threatening in individuals who have severe spontaneous bleeding resulting from minor trauma or surgery. Although replacement therapy of the missing exogenous factor has improved patients' quality of life, it has not been possible to establish a long-term treatment. Due to the severity of the disease and the need for repetitive doses throughout the patient's life, replacement therapy has become a high-cost treatment option; therefore, the development of self-sustainable long-term therapies is critical. Hemophilia is a good candidate for gene therapy because it is a monogenic disease that can be counteracted by expression of the missing factor. In this article, we review some of the most relevant advances in gene therapy for this illness. PMID: 32661215 [PubMed - in process]
Source: Journal of Biosciences - Category: Biomedical Science Authors: Tags: J Biosci Source Type: research